New eye drug shows promise for dry AMD in early trial

NCT ID NCT07160179

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 21 times

Summary

This study tests a new medicine called ABBV-6628 for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. About 66 adults aged 50 and older will receive injections into the eye to see if the drug is safe and how it works. The trial compares ABBV-6628 to an approved treatment (SYFOVRE) and involves regular checkups over about 22 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Retina Consultants - The Woodlands /ID# 262138

    RECRUITING

    The Woodlands, Texas, 77384, United States

  • Retina Foundation of the Southwest /ID# 262479

    RECRUITING

    Dallas, Texas, 75231, United States

    Contact Phone: •••-•••-••••

  • Retina Partners Midwest, P.C. /ID# 262172

    RECRUITING

    Carmel, Indiana, 46032, United States

  • Retina Research Institute of Texas /ID# 262141

    RECRUITING

    Abilene, Texas, 79606-1224, United States

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.